📰 Pharma Communications News
Pharma Communications News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharma Communications. Real-time updates on events, politics, business and more.
April 20, 2023
Agency receives three additional nominations for the PRWeek U.S. Healthcare + Pharma Communications AwardsPARSIPPANY, N.J., April 20, 2023 /PRNews...
October 26, 2022
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, in idiopat...
September 5, 2022
InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at...
May 15, 2022
/PRNewswire/ -- Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was...
May 15, 2022
/PRNewswire/ -- Today, Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, that was...
May 12, 2022
Highlights from the PRWeek Healthcare & Pharma Comms Summit. From PR Week
May 12, 2022
The winners of the 2022 Healthcare & Pharma Communications Awards. From PR Week
May 11, 2022
The winners of the 2022 Healthcare + Pharma Communications Awards. From PR Week
May 10, 2022
Breakfast Briefing: 5 things for PR pros to know on Tuesday morning. From PR Week
March 22, 2022
PRWeek US Healthcare + Pharma Communications Awards 2022 shortlist revealed. From PR Week